Zoetis Stock Price Target and Analyst Ratings (NYSE:ZTS)

Analyst Price Target for ZTS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$167.25

▲ +7.14% Upside Potential

This price target is based on 15 analysts offering 12 month price targets for Zoetis in the last 3 months. The average price target is $167.25, with a high forecast of $203.00 and a low forecast of $126.00. The average price target represents a 7.14% upside from the last price of $156.10.

Buy

The current consensus among 15 investment analysts is to buy stock in Zoetis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

9/4/2019

0 strong buy ratings
8 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

12/3/2019

1 strong buy ratings
8 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

3/2/2020

1 strong buy ratings
8 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

5/31/2020

1 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

8/29/2020

1 strong buy ratings
8 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

11/27/2020

1 strong buy ratings
8 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
8 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

2/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/17/2021	Credit Suisse Group	Boost Price Target		$197.00 ➝ $203.00	Low	i
11/13/2020	Morgan Stanley	Boost Price Target	Equal Weight	$167.00 ➝ $174.00	Low	i
11/12/2020	Truist	Boost Price Target		$160.00 ➝ $170.00	Low	i
11/6/2020	Barclays	Boost Price Target	Overweight	$175.00 ➝ $189.00	Medium	i
9/21/2020	Atlantic Securities	Initiated Coverage	Overweight	$191.00	Low	i
8/20/2020	Morgan Stanley	Boost Price Target	Neutral ➝ Equal Weight	$125.00 ➝ $167.00	Low	i
8/14/2020	Edward Jones	Upgrade	Hold ➝ Buy		Low	i
8/12/2020	G.Research	Downgrade	Buy ➝ Hold		Low	i Rating by K. Kedra at G.Research, Llc
8/12/2020	Gabelli	Downgrade	Buy ➝ Hold		Low	i
8/10/2020	Truist Financial	Boost Price Target	Neutral ➝ Hold	$112.00 ➝ $160.00	Low	i
8/10/2020	Citigroup	Boost Price Target	Neutral	$146.00 ➝ $160.00	Low	i
8/7/2020	Stifel Nicolaus	Boost Price Target	Top Pick ➝ Buy	$155.00 ➝ $170.00	Medium	i
7/30/2020	Citigroup	Boost Price Target	Neutral	$131.00 ➝ $146.00	Medium	i
7/20/2020	Bank of America	Boost Price Target	Neutral	$135.00 ➝ $150.00	Medium	i Rating by Michael Ryskin at Bank of America Co.
6/3/2020	Argus	Reiterated Rating	Buy		Low	i
5/27/2020	Jefferies Financial Group	Initiated Coverage	Buy	$152.00	High	i
5/18/2020	Credit Suisse Group	Reiterated Rating	Buy	$147.00	High	i
5/8/2020	UBS Group	Lower Price Target	Neutral	$146.00 ➝ $126.00	Low	i
5/8/2020	Citigroup	Lower Price Target	Neutral	$139.00 ➝ $131.00	Low	i
5/7/2020	Barclays	Boost Price Target	Overweight	$129.00 ➝ $140.00	Medium	i
4/2/2020	Morgan Stanley	Lower Price Target	Equal Weight	$148.00 ➝ $125.00	High	i
3/31/2020	G.Research	Upgrade	Hold ➝ Buy		High	i Rating by K. Kedra at G.Research, Llc
2/28/2020	The Goldman Sachs Group	Reiterated Rating	Buy	$162.00	High	i Rating by Nathan Rich at The Goldman Sachs Group, Inc.
2/19/2020	UBS Group	Boost Price Target	Neutral	$126.00 ➝ $146.00	Low	i
2/14/2020	Morgan Stanley	Boost Price Target	Equal Weight	$136.00 ➝ $148.00	Low	i Rating by David Risinger at Morgan Stanley
2/14/2020	SunTrust Banks	Reiterated Rating	Hold	$145.00	Low	i
2/13/2020	Cfra	Upgrade	Buy ➝ Strong-Buy	$147.00 ➝ $160.00	Low	i
2/12/2020	Bank of America	Reiterated Rating	Hold	$145.00	Medium	i Rating by Michael Ryskin at Bank of America Co.
1/9/2020	Raymond James	Initiated Coverage	Market Perform		Low	i
12/5/2019	Bank of America	Reiterated Rating	Hold	$125.00	Low	i
10/11/2019	Credit Suisse Group	Set Price Target	Buy	$138.00	Low	i Rating by Erin Wright at Credit Suisse Group AG
9/30/2019	Morgan Stanley	Boost Price Target	Hold ➝ Equal Weight	$100.00 ➝ $136.00	Low	i
9/13/2019	Stifel Nicolaus	Set Price Target	Buy	$140.00	Medium	i Rating by Jonathan Block at Stifel Nicolaus
9/11/2019	Credit Suisse Group	Reiterated Rating	Buy	$130.00	High	i
9/9/2019	The Goldman Sachs Group	Initiated Coverage	Conviction-Buy	$145.00	Medium	i
9/4/2019	Argus	Set Price Target	Buy	$140.00	Low	i Rating by Jasper Hellweg at Argus
8/13/2019	SunTrust Banks	Boost Price Target	Hold	$120.00 ➝ $130.00	Low	i
8/7/2019	Craig Hallum	Boost Price Target	Buy	$132.00 ➝ $138.00	Low	i
8/7/2019	Barclays	Boost Price Target	Overweight	$120.00 ➝ $135.00	Low	i Rating by Balaji Prasad at Barclays PLC
7/22/2019	Stifel Nicolaus	Boost Price Target	Buy	$110.00 ➝ $130.00	Medium	i
7/1/2019	Bank of America	Downgrade	Buy ➝ Neutral	$111.00 ➝ $120.00	Low	i
6/25/2019	Craig Hallum	Boost Price Target	Buy	$114.00 ➝ $132.00	Low	i
6/12/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$116.00 ➝ $130.00	Low	i
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$120.00	Low	i
5/23/2019	Guggenheim	Initiated Coverage	Buy ➝ Buy	$114.00	Low	i
5/9/2019	BMO Capital Markets	Boost Price Target	Market Perform	$101.00 ➝ $105.00	Low	i
5/2/2019	Gabelli	Downgrade	Buy ➝ Hold	$108.00	Low	i Rating by K. Kedra at Gabelli
4/2/2019	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$102.00 ➝ $112.00	Low	i
3/20/2019	UBS Group	Initiated Coverage	Neutral		Low	i
3/19/2019	SunTrust Banks	Initiated Coverage	Hold ➝ Hold	$100.00	Low	i
3/4/2019	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$97.00 ➝ $110.00	Medium	i
2/25/2019	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$93.00 ➝ $101.00	Low	i
1/23/2019	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$86.00	Low	i
11/13/2018	Argus	Set Price Target	Buy	$105.00	Medium	i Rating by Jasper Hellweg at Argus
11/12/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Neutral	$93.00	Low	i
11/11/2018	BMO Capital Markets	Reiterated Rating	Hold		Low	i
11/2/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $101.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
11/2/2018	Morgan Stanley	Set Price Target	Hold	$100.00	Low	i Rating by David Risinger at Morgan Stanley
10/17/2018	Cantor Fitzgerald	Reiterated Rating	Overweight	$98.00 ➝ $105.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
10/15/2018	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$100.00	Medium	i
10/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$98.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
8/21/2018	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$95.00	High	i
8/14/2018	Argus	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $103.00	Low	i
8/3/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$86.00 ➝ $95.00	Low	i
8/3/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Hold	$87.00 ➝ $92.00	Low	i Rating by David Risinger at Morgan Stanley
8/2/2018	BMO Capital Markets	Reiterated Rating	Hold	$82.00	High	i Rating by Alex Arfaei at BMO Capital Markets
8/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$98.00	High	i Rating by Louise Chen at Cantor Fitzgerald
7/30/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$97.00 ➝ $100.00	Low	i
7/27/2018	Cantor Fitzgerald	Set Price Target	Buy	$98.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
7/13/2018	Jefferies Financial Group	Set Price Target	Buy	$96.00	Medium	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
6/6/2018	Cantor Fitzgerald	Set Price Target	Buy	$98.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
5/16/2018	BMO Capital Markets	Reiterated Rating	Hold	$80.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
5/16/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$98.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
5/1/2018	Cantor Fitzgerald	Set Price Target	Buy	$90.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
4/25/2018	Craig Hallum	Reiterated Rating	Buy	$87.00 ➝ $94.00	Low	i
4/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$90.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
4/19/2018	Hilliard Lyons	Downgrade	Neutral		Low	i
4/19/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $98.00	Low	i Rating by Liav Abraham at Citigroup Inc.
4/13/2018	Jefferies Financial Group	Reiterated Rating	Buy	$96.00	Low	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/5/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$83.00 ➝ $89.00	Low	i
3/19/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$70.00	Low	i Rating by David Risinger at Morgan Stanley
2/26/2018	Jefferies Financial Group	Set Price Target	Buy	$97.00	Low	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/17/2018	Barclays	Set Price Target	Hold	$77.00	Medium	i Rating by Douglas Tsao at Barclays PLC
2/16/2018	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold ➝ Hold	$76.00 ➝ $78.00	Low	i
2/16/2018	Piper Jaffray Companies	Set Price Target	Buy	$88.00	Low	i Rating by Brett Wong at Piper Jaffray Companies
2/16/2018	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $86.00	Medium	i
2/16/2018	Bank of America	Boost Price Target	Buy	$80.00 ➝ $87.00	Medium	i
2/15/2018	Cantor Fitzgerald	Set Price Target	Buy	$90.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
2/15/2018	BMO Capital Markets	Set Price Target	Hold	$78.00	Medium	i Rating by Alex Arfaei at BMO Capital Markets
2/15/2018	Cowen	Set Price Target	Buy	$85.00	Medium	i Rating by Steve Scala at Cowen Inc
1/22/2018	BMO Capital Markets	Set Price Target	Hold	$78.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
1/18/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$86.00	Low	i Rating by Brett Wong at Piper Jaffray Companies
1/16/2018	Jefferies Financial Group	Reiterated Rating	Buy	$89.00	High	i
1/11/2018	Cantor Fitzgerald	Set Price Target	Buy	$85.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
1/9/2018	BMO Capital Markets	Boost Price Target	Positive ➝ Market Perform	$78.00	Medium	i Rating by Alex Arfaei at BMO Capital Markets
1/8/2018	BMO Capital Markets	Reiterated Rating	Hold		Low	i Rating by Alex Arfaei at BMO Capital Markets
1/4/2018	Citigroup	Upgrade	Neutral ➝ Buy	$85.00	Low	i Rating by Liav Abraham at Citigroup Inc.
1/2/2018	Craig Hallum	Reiterated Rating	Buy	$77.00 ➝ $85.00	Low	i
1/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$85.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
12/26/2017	Cantor Fitzgerald	Set Price Target	Buy	$85.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
12/12/2017	Cantor Fitzgerald	Set Price Target	Buy	$80.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
11/29/2017	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$80.00	Low	i
11/24/2017	UBS Group	Reiterated Rating	Buy ➝ Neutral		N/A	i
11/17/2017	Cowen	Set Price Target	Buy	$70.00 ➝ $80.00	N/A	i Rating by Steve Scala at Cowen Inc
11/10/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
11/3/2017	BMO Capital Markets	Boost Price Target	Market Perform	$65.00 ➝ $70.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
11/3/2017	Morgan Stanley	Boost Price Target	Equal Weight	$61.00 ➝ $70.00	N/A	i
11/2/2017	BMO Capital Markets	Reiterated Rating	Hold	$65.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
10/31/2017	Cantor Fitzgerald	Set Price Target	Buy	$75.00	N/A	i Rating by Louise Chen at Cantor Fitzgerald
10/25/2017	BMO Capital Markets	Set Price Target	Hold	$65.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
10/24/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	N/A	i Rating by Louise Chen at Cantor Fitzgerald
10/24/2017	Stifel Nicolaus	Reiterated Rating	Buy	$65.00	N/A	i
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
9/6/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
9/1/2017	Stifel Nicolaus	Reiterated Rating	Buy	$65.00	Low	i
8/25/2017	Piper Jaffray Companies	Set Price Target	Buy	$73.00	Low	i
8/24/2017	Cowen	Set Price Target	Buy	$70.00	Low	i Rating by Steve Scala at Cowen Inc
8/14/2017	Cantor Fitzgerald	Set Price Target	Buy	$75.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
8/7/2017	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$62.00	Low	i
7/25/2017	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$65.00	High	i
7/21/2017	Stifel Nicolaus	Reiterated Rating	Buy	$65.00	Low	i
7/17/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$62.00 ➝ $65.00	Low	i
7/17/2017	Cowen	Set Price Target	Buy	$70.00	Low	i Rating by Steve Scala at Cowen Inc
7/11/2017	Cowen	Set Price Target	Buy	$60.00	Low	i
6/20/2017	Hilliard Lyons	Initiated Coverage	Buy	$77.00	Low	i
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$75.00	Low	i
6/13/2017	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$64.00 ➝ $65.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
5/30/2017	Argus	Reiterated Rating	Buy	$60.00 ➝ $69.00	Low	i
5/26/2017	CL King	Initiated Coverage	Buy ➝ Buy	$71.00	Low	i
5/24/2017	Credit Suisse Group	Boost Price Target	Outperform	$61.00 ➝ $67.00	Low	i
5/9/2017	Jefferies Financial Group	Boost Price Target	Buy	$65.00 ➝ $70.00	Low	i
5/4/2017	BMO Capital Markets	Reiterated Rating	Buy	$60.00	High	i Rating by Alex Arfaei at BMO Capital Markets
3/15/2017	Craig Hallum	Initiated Coverage	Buy	$65.00	Low	i
2/19/2017	BMO Capital Markets	Reiterated Rating	Outperform	$60.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
2/16/2017	Guggenheim	Boost Price Target	Buy	$60.00 ➝ $65.00	N/A	i Rating by Louise Chen at Guggenheim
2/16/2017	Off Wall Street	Reiterated Rating	Strong Sell	$35.00	N/A	i
2/8/2017	BMO Capital Markets	Reiterated Rating	Buy	$60.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
1/20/2017	Jefferies Financial Group	Boost Price Target	Buy	$62.00 ➝ $64.00	N/A	i
12/23/2016	Guggenheim	Reiterated Rating	Buy	$60.00	N/A	i
12/23/2016	BMO Capital Markets	Reiterated Rating	Outperform	$59.00	N/A	i
12/20/2016	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$62.00	N/A	i
12/20/2016	Jefferies Financial Group	Reiterated Rating	Buy	$62.00	N/A	i
12/15/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$61.00	N/A	i
12/15/2016	Cowen	Upgrade	Market Perform ➝ Outperform	$50.00 ➝ $60.00	N/A	i
11/3/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$53.00	N/A	i
10/16/2016	Jefferies Financial Group	Reiterated Rating	Buy	$63.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
10/12/2016	Stifel Nicolaus	Reiterated Rating	Buy	$58.00	N/A	i Rating by Jonathan Block at Stifel Nicolaus
9/29/2016	Bank of America	Initiated Coverage	Buy	$60.00	N/A	i
9/14/2016	Jefferies Financial Group	Reiterated Rating	Buy	$60.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/9/2016	Argus	Boost Price Target	Below Average	$54.00 ➝ $58.00	N/A	i
9/7/2016	Credit Suisse Group	Reiterated Rating	Focus List	$60.00	N/A	i Rating by Erin Wilson at Credit Suisse Group AG
8/23/2016	Credit Suisse Group	Reiterated Rating	Outperform	$60.00	N/A	i Rating by Erin Wilson at Credit Suisse Group AG
8/23/2016	Jefferies Financial Group	Reiterated Rating	Buy	$60.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
8/22/2016	Guggenheim	Reiterated Rating	Positive	$60.00	N/A	i Rating by Louise Chen at Guggenheim
8/4/2016	Jefferies Financial Group	Boost Price Target	Buy	$58.00 ➝ $60.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
8/4/2016	Citigroup	Boost Price Target	Neutral	$50.00 ➝ $53.00	N/A	i Rating by Liav Abraham at Citigroup Inc.
8/4/2016	Barclays	Boost Price Target	Equal Weight	$45.00 ➝ $49.00	N/A	i
7/18/2016	Guggenheim	Reiterated Rating	Buy	$60.00	N/A	i Rating by Louise Chen at Guggenheim
6/14/2016	Jefferies Financial Group	Reiterated Rating	Buy	$57.00 ➝ $58.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
6/10/2016	Citigroup	Downgrade	Buy ➝ Neutral	$46.00 ➝ $50.00	N/A	i
5/31/2016	Stifel Nicolaus	Initiated Coverage	Buy	$58.00	N/A	i
5/22/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Erin Wilson at Credit Suisse Group AG
5/8/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
5/6/2016	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$46.00 ➝ $48.00	N/A	i
5/4/2016	Guggenheim	Reiterated Rating	Buy	$60.00	N/A	i Rating by Louise Chen at Guggenheim
3/15/2016	Jefferies Financial Group	Boost Price Target	Buy	$50.00 ➝ $53.00	N/A	i

(Data available from 2/26/2016 forward)

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $156.10

$155.00

$157.37

50 Day Range

MA: $161.92

$153.15

$169.39

52 Week Range

Now: $156.10

$90.14

$176.64

Volume

18,585 shs

Average Volume

1,926,265 shs

Market Capitalization

$74.17 billion

P/E Ratio

46.32

Dividend Yield

0.63%

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Zoetis?

The following Wall Street analysts have issued research reports on Zoetis in the last twelve months: Argus, Atlantic Securities, Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Edward Jones, G.Research, Llc, Gabelli, Jefferies Financial Group Inc., Morgan Stanley, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for ZTS.

What is the current price target for Zoetis?

12 Wall Street analysts have set twelve-month price targets for Zoetis in the last year. Their average twelve-month price target is $167.25, suggesting a possible upside of 6.9%. Credit Suisse Group AG has the highest price target set, predicting ZTS will reach $203.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $126.00 for Zoetis in the next year.
View the latest price targets for ZTS.

What is the current consensus analyst rating for Zoetis?

Zoetis currently has 7 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZTS will outperform the market and that investors should add to their positions of Zoetis.
View the latest ratings for ZTS.

What other companies compete with Zoetis?

Other companies that are similar to Zoetis include Johnson & Johnson, Eli Lilly and, AbbVie, Merck & Co., Inc., Pfizer, Bristol-Myers Squibb, Horizon Therapeutics Public, Royalty Pharma, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics, Endo International and Supernus Pharmaceuticals.

How do I contact Zoetis' investor relations team?

Zoetis' physical mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company's listed phone number is 973-822-7000 and its investor relations email address is [email protected] The official website for Zoetis is www.zoetis.com.

NYSE:ZTS - Zoetis Stock Price Target and Predictions

Analyst Price Target for ZTS

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Zoetis?

What is the current price target for Zoetis?

What is the current consensus analyst rating for Zoetis?

What other companies compete with Zoetis?

How do I contact Zoetis' investor relations team?